Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07323479
ABSTRACT:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4810643 (1989-03-01), Souza
patent: 4999291 (1991-03-01), Souza
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5528823 (1996-06-01), Rudy, Jr. et al.
patent: 5580755 (1996-12-01), Souza
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6140346 (2000-10-01), Andrulis, Jr. et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 2001/0018445 (2001-08-01), Huang et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0128228 (2002-09-01), Hwu
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0013739 (2003-01-01), Masferrer et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0266809 (2004-12-01), Emanuel
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 99/47512 (1999-09-01), None
patent: WO 01/70275 (2001-09-01), None
patent: WO 01/087307 (2001-11-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
Cancer: Principles and Practice of Oncology 6th Edition (2001) Lippincott Williams & Wilkins.
temozolomide. The Royal Society of Medicine: Medicines (2002). Retrieved Jul. 3, 2006, from xreferplus. http://www.xreferplus.com/entry/2129458.
Burgio et al. Effects of P-glycoprotein Modulator on Etoposide Elimination and Central Nervous System Distribution J of Pharmacology and Experimental Therapeutics 287:911-917 (1998).
Temodar. Dorland's Illustrated Medical Dictionary (2003). Retrieved Jul. 3, 2006, from xreferplus. http://www.xreferplus.com/entry/4200902.
http://virtualtrials.com/cpt11.cfm retrieved Jul. 3, 2006.
Coyle et al. Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol (1990) 8(12):2014-8.
Carmustine. Mosby's Medical, Nursing and Allied Health Dictionary (2002). Retrieved Jul. 3, 2006, from xreferplus. http://www.xreferplus.com/entry/3031349.
Blaney et al. Phase II evaluation of topotecan for pediatric central nervous system tumors Cancer (1996) 78(3):527-31.
Alexanian et al., 2004, “VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma,” Am. Soc. Hematol. 46thAnn. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #210.
Anderson, 2000, “Thalidomide: Therapeutic potential in hematologic malignancies,” Seminars in Hematology 37(1 Supp 3): 1-4.
Attal et al., 2004, “Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02),” Am. Soc. Hemtaol. 46thAnn. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #535.
Bernardeschi et al., 2003, J. Exp. Clin. Cancer Res. 22(4):129-133.
Corral et al., 1999, “Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha,” J. Immunol. 163(1):380-386.
Davies et al., 2001, “Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma,” Blood 98(1):210-216.
Dimopoulos et al., 2004, “Primary treatment with puilsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≧75 years of age,” Am. Soc. Hematol. 46thAnn. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482.
Eisen et al., 2000, “Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer,” Br. J. Cancer 82(4):812-817.
Fakhouri et al., 2004, “Thalidomide in patients with multiple myeloma and renal failure,” Br. J. Haematol. 125:90-102.
Fenk et al., 2005, “Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma,” Leukemia 19(1):156-159.
Gupta et al., 2001, “Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications,” Leukemia 15(12):1950-1961.
Haslett et al., 2003, “Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro,” J. Infect. Dis. 187(6):946-955.
Hideshima et al., 2000, “Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy,” Blood 96(9):2943-2950.
Offidani et al., 2003, Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica. Dec. 2003;88(12):1432-1433.
Palumbo et al.,
Celgene Corporation
Jones Day
Kwon Brian
LandOfFree
Methods for treatment and management of brain cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment and management of brain cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment and management of brain cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2803953